Pharmaceuticals and biotechnology in London
At Allen & Overy LLP, Jim Ford leads the London IP practice and is co-chair of the global life sciences group and Marc Doring heads the UK IP litigation team. The group offers the full spectrum of specialisms; mergers and acquisitions, commercial transactions, IP, financing and regulatory matters. Matthew Appleton focuses on corporate transactions for life sciences clients and the 'excellent' Marjan Noor is highly rated for her handling of IP and regulatory matters. Neville Cordell and senior associate Rafi Allos tackle IP litigation together with regulatory work. Many of the team have science backgrounds - there is a team of science analysts based in Belfast and the team has a specific focus on the area of gene editing. It also offers a comprehensive range of expertise from regulatory to distribution and advertising in respect of the challenges associated with the medicinal applications of cannabis.
‘Top quality work product. Sensible. Thoughtful. Good at anticipating clients needs.’
‘Michael Snook is mature, easy to deal with and very straightforward.’
Premaitha Health plc (now Yourgene Health)
- Represented Premaitha Health, which has developed the first CE marked non-invasive prenatal test for chromosomal aneuploidies. It defended patent infringement claims under five separate patents brought by a number of parties, but the matter was settled prior to a Court of Appeal hearing.
- Successfully acted for Regeneron, the US biopharmaceutical company, in bringing patent infringement proceedings against Kymab Limited, a UK biotechnology company.
- Acting for a global pharma company in a Supreme Court appeal in respect of a blockbuster drug.
- Advising BTG plc on the recommended offer by Boston Scientific Corporation. The boards reached agreement on the terms of a recommended offer to be implemented under the City Code on Takeovers and Mergers by way of a UK scheme of arrangement. Advice to the client included competition issues in a deal valued at £3.3bn.
- Advised GN Hearing on all aspects (from term sheet to signed documents) of its multi-agreement “Smart Hearing” collaboration with Cochlear. This included complex IP licensing arrangements to take account of perpetual cross-licensing.
Bird & Bird LLP is known for its 'hard core' IP strength in the life sciences sector. Mark Hilton, who co-heads the life sciences and healthcare group with Sally Shorthose, is highly regarded for his deft handling of complex patent litigation. Noted for her 'good negotiating skills' Shorthose has a focus on the transactional side of IP and regulatory regimes. Corporate partner James Baillieu has joined the team from Norton Rose Fulbright. Other members of the patent disputes group include Tim Harris , Eleanor Root and associate Chris de Mauny. In addition to its IP skills, the team also handles a range of commercial work such as collaborations and licensing matters together with regulatory matters.
Mark Hilton; Sally Shorthose
‘A strong team with a wealth of technical understanding of industry areas and a stellar track record of work in key areas.’
‘B&B are consistently high quality. You know what you are going to get – whilst the fees are high, they will leave no stone unturned progressing shrewd and practical strategies.’
‘They remain at the pinnacle of the profession as regards their life sciences work.’
‘Mark Hilton provides calm, clear-headed advice and has a keen eye for detail and an understanding of the broader context.’
‘Mark Hilton is a match for anyone as a pharma-focused patent litigator. His deep industry knowledge sets him apart from much of the rest of the field. He is calm under pressure and is able to avoid being sidetracked, which is quite a skill in complex patent litigation. There is no one better at 4D chess.’
Actavis (acquired by Accord Healthcare)
Guy’s and St Thomas’s NHS Foundation Trust
Fisher & Paykel Healthcare
- Acting for Allergan in High Court revocation proceedings brought by Aspire and Accord in respect of a patent owned by Allergan for an enhanced ophthalmic solution which has approximate annual UK sales of £16.5m. This litigation is complicated by regulatory issues and approvals.
- Assisting eZono on a number of alliance and collaboration agreements with international partners for the licensing and integration of its guiding procedural ultrasound technology into partner products. The work included drafting and negotiating collaboration and alliance agreements and addressing complex IP licensing and ownership arrangements. The Hong Kong office assisted as a number of the partners are based in Asia-Pacific.
- Advising Guy’s and St Thomas’s NHS Foundation Trust on a range of matters including commercial projects for the provision of healthcare to technology agreements and procurement.
- Advised Calero Software, a leading global provider of Communications and Cloud Lifecycle Management software and managed services, in acquiring the entire issued share capital of Scotland-based Veropath Limited, a leading provider of telecom expense management solutions throughout the UK and Europe.
With 'enormous strength in the pharma and biotech space' Bristows LLP attracts acclaim from clients as a go-to practice. Laura Anderson and 'outstanding' Liz Cohen are the joint heads of the life sciences group and Brian Cordery who 'knows his stuff' jointly heads patent litigation with Myles Jelf. The team offers an all-round service to clients covering the core areas of transactional, regulatory and IP expertise. Its skills also extend to areas where tech intersects with life sciences or healthcare and the handling of, for example, medical data. 'Excellent regulatory expert' Alex Denoon heads the regulatory group and with a PhD in molecular biology, litigator Dr Robert Burrows is 'one of the most knowledgeable solicitors in the pharma/biotech space'. The 'talented' Gemma Barrett is a litigator within life sciences and 'creative thinker' Greg Bacon and senior associate Rachel Mumby are also recommended.
Laura Anderson; Liz Cohen
Other key lawyers:
‘They have well-qualified solicitors with technical backgrounds who are familiar with the science immediately. They are a large enough team to cope with large cases and demanding clients. There are excellent juniors of whom the more senior team are very supportive. A huge pleasure to work with and they get great results.’
‘The Bristows team provided exceptionally good work. All team members were very responsive and open for discussions. Their written work product was likewise spotless and, unlike the work product of most other firms that I have worked with, there was no need for fine tuning.’
‘Bristows was able to grasp our technically complex case quickly and helped to advance our global litigation strategy even beyond the UK with their vast experience in this field.‘
‘There is a real focus on life sciences and technology at the firm, with all the specialist teams a pharmaceutical company needs in the same place – IP, regulatory, competition. They are always willing to provide excellent, current and useful training.’
‘The team really cares about doing a good job and always go the extra mile. Although a partner-led service, you also get to know the associates who are doing the work.‘
‘Rob Burrows is one of the most knowledgeable solicitors in the pharma/biotech space. He explains difficult concepts so well to clients and is easy to work with.’
‘Greg Bacon is a creative thinker – he can propose innovative options as solutions.’
‘Alex Denoon is an excellent regulatory expert. It’s a great experience working with him.’
‘Rachel Mumby is a talented solicitor- technically excellent and great with clients.’
‘Olivia Henry is a brilliant young solicitor with great knowledge and ability. One to watch’.
‘Every one of Dominic Adair, Gregory Bacon and Gemma Barrett is particularly talented in their area.’
‘Dominic Adair did a great job in coordinating all activities of our case. He is very pleasant to work with. He is a bright mind and yet remained very modest. I can highly recommend him for any IP litigation in the UK and will certainly work with him again in the future.’
‘Dom Adair is technically gifted, understands issues quickly and gives great commercial advice.’
‘Brian Cordery is incredibly responsive and diligent, knows his stuff and thinks the case through carefully.’
‘Gemma Barrett provides very clear and commercial advice.’
Johnson & Johnson (Janssen Sciences)
Google and DeepMind
- Advising Genomics England (UK Department of Health) on a range of matters including on a commercial technology collaboration with IQVIA, under which IQVIA will develop its platform to accommodate genomic data and advised on the IT and IP issues relating to its pioneering PanelApp.
- Assisted Searle (Pfizer) and Janssen (Johnson & Johnson) in their successful defence of SPC revocation proceedings commenced by Sandoz and Hexal. The matter concerned Janssen’s blockbuster medication for the treatment of HIV-1. The Court of Appeal referred a question on the matter to the European Court.
- Advised Syncona, as lead investor, in the £14m Series A financing for OMass Therapeutics Limited. This financing is intended to enable OMass to develop a pipeline of novel drug development programmes.
- Represent EVER Neuro, a company focused on the research, development, production and commercialisation of products in the areas of neurology, critical care, anesthesia and oncology. Ever Neuro holds a Marketing Authorisation medicine granted by the MHRA in respect of a generic version of an existing medicine. Orion holds the Marketing Authorisation in respect of the existing medicine. Orion has asked the Court to revoke the Marketing Authorisation granted to the client who is an interested party in the proceedings. In a complex case, Orion asked for a question to be referred to the CJEU to seek to change the current CJEU jurisprudence.
- Continues to act for long-standing client Novartis Pharma AG, with the enforcement of its patents for its blockbuster medicines.
The life sciences and healthcare division of CMS, headed by Sarah Hanson and Robert Stephen, is noted for its 'excellent and commercial advice and efficiency'. It offers specialists in all areas pertinent to life sciences and healthcare including transactional work, IP and regulatory regimes. Shuna Mason specialises in product liability and regulations and Gareth Morgan focuses on IP protection and regulatory compliance. Caroline Hobson provides sector specific competition advice, for which Carina Healey in Glasgow is also noted. The team is involved in advising on projects where healthcare and technology meet.
Sarah Hanson; Robert Stephen
‘The pharmaceutical and biotechnology advisors have in-depth knowledge of the risks and challenges faced by the industry and by global companies in the industry. Their European network of advisors provides the ability to advise within multiple jurisdictions without the administrative burden of engaging separate law firms for each piece of advice or project.‘
‘Sarah Hanson has acted as our relationship partner and has always responded quickly and helped to select appropriate advisors within the CMS network for each instruction.’
‘Gareth Morgan has displayed exceptional in-depth knowledge of our products and the science behind them, which makes his IP and regulatory advice invaluable.’
‘The new Pan-Asia and Pacific network created by Nick Beckett in the Beijing office has provided a value-add network in the region which has helped to support the growth of our business in Asia.’
‘Carina Healey has proved to be very good; she provides clear advice on complex issues [in Glasgow].‘
‘Caroline Hobson gives practical and sensible advice and understands the business.‘
‘Shuna Mason understand the business in great detail.’
Francis Crick Institute
Johnson & Johnson
The Wellcome Trust
- Acted for Silence Therapeutics, a leader in RNA therapeutics for the treatment of serious diseases, in patent infringement and revocation proceedings brought against Alnylam Pharmaceuticals. As well as the UK litigation, co-ordinated claims brought in the Netherlands and Portugal and related European Patent Office proceedings.
- Advised GlaxoSmithKline Plc on the UK’s only ever ‘reverse patent settlement’ investigation and one of the most high-profile UK prohibitive competition law inquiries, and on its appeal to the Competition Appeal Tribunal and current reference to the European Court of Justice.
- Continuing to advise long-standing client University College London on a number of high-profile strategic research collaborations involving various academic institutions with significant funding from the UK research councils and charity partners.
- Successfully defended Sandoz against both patent infringement proceedings and a regulatory challenge mounted against its pharmaceutical product authorisations. Also advising on the client’s claim on the cross-undertakings in damages against Napp Pharmaceuticals.
Alan Montgomery is the global co-head of the Herbert Smith Freehills LLP pharmaceuticals and healthcare sector team, together with Shaun McVicar in Melbourne. It is home to a world-class patent litigation team acting for global pharmaceutical companies; Sophie Rich and Sebastian Moore are two of the key patent litigators whilst Montgomery handles an impressive range of M&A, restructuring, joint venture and commercial mandates in the life sciences sector. Jonathan Turnbull's expertise includes protection of rights in small molecule and biological products and Chris Parker handles a broad range of disputes in the sector.
‘A top-tier team, very impressive.’
‘Mark Shillito, Joel Smith and Andrew Moir are all brilliant lawyers, strategic thinkers with great client skills.’
Ariosa Diagnostics, Inc. (part of the Roche group)
Strides Pharma Science
F Hoffmann-La Roche
- Representing Ariosa (a member of the Roche group) in patent infringement proceedings brought against it in relation to its Harmony non-invasive prenatal test.
- Advised Aurobindo Pharma on its acquisition of the commercial operations and certain supporting infrastructure of Apotex in the Netherlands, Belgium, Spain, Poland and the Czech Republic, and entry into related commercial and licensing arrangements.
- Coordinating the enforcement and defence of Gilead’s SPCs that protects Gilead’s HIV medicines in Europe. Litigation is being conducted in numerous European countries.
- Advising Strides and related entities in a series of complex cross-border transactions which involve advice on mergers, acquisition finance and product supply arrangements.
- Advising F Hoffmann La-Roche AG and Roche Products Limited on their defence against Pfizer Limited’s claim in the UK High Court for so-called ‘Arrow declarations’ relating to pending European Patent applications owned by Roche.
Hogan Lovells International LLP is home to a blend of IP litigation, product liability, regulatory and transactional skills backed up by the firm's global network and is consequently highly rated for 'a well-rounded' service. Stephen Bennett has a focus on contentious cases involving patent protection and dealing with SPCs and generics (he headed the team that was successful in the landmark UK Supreme Court decision for Eli Lilly in relation to generic attacks on its oncology product). John Meltzer and Matthew Felwick are well known for their specialism in relation to product liability in the life sciences sector, and counsel Jane Summerfield deals with regulatory matters relating to clinical trials, marketing authorisations, manufacturing and distribution.
Stephen Bennett; Matthew Felwick
‘The Hogan Lovells London team is extremely experienced in life sciences and clearly understand our needs. They have a very pragmatic approach and the partners are generally easily reachable – their response time in cases of urgent matters is very good.’
‘The team’s strength is that they are reliable and knowledgeable in their area of expertise. They have a good understanding of our business and provide the advice that we are looking for in a satisfactory way – not always the case with other firms (surprisingly). Individuals are responsive and trustworthy.’
Merck Sharp & Dohme
The Association of BritishPharmaceutical Industry
- The team has won a landmark UK Supreme Court decision for Eli Lilly in relation to the generic attacks on its oncology product, Alimta.
- Advising the Association of the British Pharmaceutical Industry and a number of international pharmaceutical companies on the implications of Brexit for the entire UK pharmaceutical industry. This has included advising on the process from both a UK and EU perspective, and helping to identify the key issues that will need to be addressed in the withdrawal agreement.
- Assisted an international pharmaceutical company negotiate an acceptable price with the Department for Health and Social Care for an innovative cancer drug.
- Acting for Zimmer Biomet and various European subsidiaries in relation to personal injury claims concerning Biomet’s metal-on-metal prosthetic hip replacements. The team is coordinating the defence of claims across Europe.
- Routinely advises clients in the medical devices sector on their engagement with the accreditation and conformity assessment regulators, in connection with questions raised about transfers of medical devices certificates. Also advises on data protection and privacy matters.
The Simmons & Simmons healthcare and life sciences group is headed by Michael Gavey (together with Alexandre Regniault in Paris). Its client roster ranges from major pharmaceutical and medical device and biotech companies to healthcare operators and charities such as the Institute of Cancer Research. Gavey also heads the IP team and digital health group and assists clients with IP-related transactions, regulatory regimes and compliance. Michael Burdon and Scott Parker deal with patent litigation, often involving multiple jurisdictions. Charles Mayo is a corporate partner who advises on a wide range of commercial and finance matters. Associate Lydia Torne is noted for her IP transactional and regulatory compliance work involving a range of healthcare products.
Boston Scientific Corporation
Alzheimers’ Research UK (ARUK)
The Institute of Cancer Research
Venture Life Group plc
- Advising on multi-jurisdictional patent litigation for Boston Scientific’s transcatheter aortic replacement technology against Edwards Lifesciences LLC. Obtained successful outcomes in the UK High Court and Court of Appeal. There is an ongoing dispute between the parties in the UK regarding the amount of damages Edwards will pay Boston Scientific, and whether Edwards’ new product infringes Boston Scientific’s patents.
- Advising Gilead in UK litigation against a number of generics in respect of its SPCs protecting Gilead’s HIV drug, TRUVADA.
- Advising GlaxoSmithKline on its strategic research collaborations including involving AI and on several multi-stakeholder projects funded under the EU Innovative Medicines Initiative and Horizon 2020 and on the impact of Brexit.
- Working with Alzheimer’s Research UK to establish the Dementia Research Institute.
- Continuing to advise long-standing client Genmab A/S in connection with various licences, collaboration agreements and commercialisation arrangements with various partners. The advice includes assisting with manufacturing and supply arrangements, technology transfer arrangements and commercialisation agreements in respect of approved antibodies and pipeline products and technologies.
The Arnold & Porter team is led by Ian Dodds-Smith who is considered a 'luminary' when it comes to regulatory and product liability cases. His expertise covers UK and European regulatory regimes and his product liability experience includes numerous group actions conducted in the UK and Europe. Lincoln Tsang is also know for his regulatory and enforcement work. He is a former senior regulator and advises clients on a raft of sectors; pharmaceuticals, biotechnology, medical devices, in vitro diagnostic devices, cosmetics and food including on public policy issues. Other team members include Adela Williams who is a registered medical practitioner specialising in regulatory regimes and group actions and Jacqueline Mulryne who has a focus on the effects of decisions by regulatory bodies.
- Acting for Amicus in an EU General Court case relating to a request for access to documents under the EMA’s disclosure policy. This is one of a group of cases against the EMA relating to disclosure of documents, that will lead to key decisions in this area. The case relates to disclosure of the client’s clinical study reports for its lead product, Galafold for the treatment of Fabry’s disease.
- Continuing to defend the regulatory data protection period that Orion believes attaches to one of its important products, Dexdor, that is used to sedate in intensive care. The case has become even larger; there is now a substantial UK element and the case has been extended to many EU member states.
- Advising Bayer on a challenge in the English courts against various clinical commissioning groups, concerning reimbursement policies. The case concerned the groups’ decision to recommend bevacizumab, a product that is not licensed for ophthalmologic indications, over and above the client’s licensed product for these indications.
- Advised GMP-Orphan on its application to the European General Court for the annulment of a decision of the European Commission to grant a marketing authorisation for the client’s drug Cuprior – which treats Wilson’s Disease – without orphan designation.
- Advising a global pharmaceutical client on matters relating to the supply Factor VIII and IX blood products in 1970s to 1990s, now the subject of a public Inquiry.
The Baker McKenzie team provides a blend of corporate, commercial and regulatory expertise to its healthcare clients backed by its extensive global network. Hiroshi Sheraton, who heads the sector group, provides deep experience of IP and regulatory regimes to global life sciences and pharma companies, and Jane Hobson focuses on cross-border mergers and acquisitions and other commercial transactions such as licensing and joint ventures. Duncan Reid-Thomas handles tech and IT-related commercial work including healthtech.
Deepmind (part of Alphabet Group)
AstraZeneca UK Ltd
- Advised Astellas, a listed Japanese pharmaceutical company, as lead counsel on the acquisition of the venture-capital backed Quethera Limited. Quethera is a gene therapy company headquartered in the UK.
- Advising IQVIA on multiple aspects of database services being built in the field of oncology. The work includes the drafting of agreements with healthcare organisations and technology suppliers and regulatory and data privacy compliance advice.
- Advised CSL and its flu vaccines division, Seqirus, on a number of significant IP-related matters; advising on an exclusive licence agreement for production of recombinant C1 esterase and advising Seqirus on the technology transfer of its flu cell culture manufacturing technology to a Japanese partner.
- Advised Cochlear on IP, commercial, corporate, competition and regulatory matters in relation to a new agreement to significantly expand their Smart Hearing Alliance collaboration with GN.
- Advised Novo Nordisk, a listed Danish multinational pharmaceutical company, on its acquisition of Ziylo, a University of Bristol spin-out company that has been pioneering the use of its platform technology – synthetic glucose binding molecules – for therapeutic and diagnostic applications.
Covington & Burling LLP
Covington & Burling LLP's life sciences group attracts plaudits for its 'well-rounded' offering. Its expertise spans corporate transactions, regulatory issues, litigation and IP as well as areas such as data privacy, anti-corruption and government affairs. It undertakes large-scale, cross-border licencing and other commercial agreements, sales and acquisitions and a range of contentious matters such as challenges to the Medicines and Healthcare Products Regulatory Agency. It is also advising on the digital healthcare sector. Grant Castle is the highly experienced head of the London team and some of his senior partners include Paul Claydon (M&A, private equity and venture capital transactions); the 'excellent' James Gubbins (corporate, technology transfers and IP) and Daniel Pavin (advisory and contentious IP and digital health technologies).
‘They have an exceptionally deep understanding of the biotech and pharmaceutical industries.’
‘They have strong subject-matter expertise in life sciences transactions.’
Horizon Discovery Group plc
Johnson & Johnson
Oxford BioMedica plc
Merck Sharpe & Dohme
Novartis International AG
ReNeuron Group plc
- Advised AstraZeneca in connection with the sale of the rights to Seroquel and Seroquel XR in the UK, China and other international markets to Luye Pharma Group Ltd.
- Acting for Boehringer Ingelheim on a challenge to the Medicines and Healthcare Products Regulatory Agency’s approval of a generic version of the client’s drug Pradaxa in the UK Courts.
- Advising Novartis on an appeal in the Court of Appeal regarding a judicial review involving the Secretary of State and 12 Clinical Commissioning Groups relating a recommendation to prescribe and dispense an unlicensed medicine in the treatment of blindness in the elderly over the client’s NICE approved drug Lucentis.
- Successfully defended Roche in the first so-called financial penalties infringement case bought by the European Commission against a pharmaceutical company using powers under the Financial Penalties Regulation.
- Assisted Sanofi in negotiating an amendment agreement to an existing collaboration and licence agreement, which expands the scope of the research collaboration between the parties with respect to mRNA-based cancer therapies.
Gowling WLG offers well-honed expertise in 'heavy' patent (and other types of IP) disputes together with commercial transactions including joint ventures, licensing and collaborations. Team head Patrick Duxbury and Luke Kempton bring impressive scientific backgrounds to their transactional IP/regulatory practice; Ian Piggin handles corporate and structuring matters and associate Jenny Davies is a life sciences patent specialist who handles pharmaceutical, biotech and medical device advisory and contentious cases.
‘Huw Evans’ expertise, practical approach and responsiveness made him a pleasure to work with.’
Heptares (Sosei Group Corporation)
Johnson & Johnson
KWS BioTest Ltd
- Acting for GlaxoSmithKline on a patent infringement matter concerning technology for making very fine powders for use in certain inhaler products. The case resulted in only the second Arrow declaration ever awarded in the UK. The opponent has appealed the decision.
- Acted for biotechnology company argenx in its global collaboration and license agreement with Halozyme Therapeutics Inc. Belgium-based argenx focuses on the clinical development of novel antibody-based therapies.
- Advised Sosei Group Corporation on an agreement with Allergan to amend its 2016 global R&D and commercialisation partnership (worth approximately €3bn) between Allergan and Sosei’s subsidiary Heptares Therapeutics.
- In a complex and long-running case, acting for Coloplast in a patent infringement case against MacGregor Healthcare in respect of the client’s patent for urinary catheters. Leave to appeal has been sought.
- Acted for Takeda in a dispute with UCB over payments being made for a licence of patents from UCB to Takeda concerned with making humanised antibodies. The claim included payment of past royalties.
Clare Tunstall heads the life sciences and patent litigation practices at Pinsent Masons LLP, which is entrusted with a range of IP protection cases by pharma and biotech companies. Christopher Sharp also takes on patent litigation cases whilst Allistair Booth focuses on IP transactions such as asset sales and purchases, collaborations and licensing. The team also assists clients on financing (Charles Waddell) and UK and European regulatory regimes (Catherine Drew). The team has been enhanced by David Lancaster, whose expertise is in patent and SPC-related litigation, joining from Powell Gilbert LLP and the arrival of Nick Finnie from Novartis.
Other key lawyers:
‘The team has an in-depth understanding of the industry and have a unique set of capabilities and skills dedicated to advise pharma clients across the whole spectrum. They are highly professional, always available and provide excellent, clear and practical advises. They can also rely on a global and European network of excellent lawyers.’
‘They have one of most impressive track records of pharma patent litigation in the UK (if not the most impressive) and before the CJEU and have been involved in several landmark decisions in the past few years.’
‘Clare Tunstall has a deep knowledge of the pharma industry, is an impressive tactician and one of the best patent litigators in the UK.’
‘Charlotte Weekes is an excellent litigator and very good at explaining complex technical issues. Catherine Drew has a unique knowledge of regulatory law in the pharma industry. They each are very nice people to work with and always make sure the client is happy.’
Teva Pharmaceutical Industries
JUUL Labs Inc
IP Group PLC
4D Pharma PLC
C4X Discovery PLC
IBSA Institut Biochimique
- The team’s work for Teva includes acting, as one of four claimants, in a challenge to the validity of two of Eli Lilly/ICOS Corporation’s patents for tadalafil – one low dosing regime patent and one formulation patent.
- Acting for Accord Healthcare against Celgene Corporation in relation to the revocation of three patent families covering the blockbuster cancer drug Revlimid.
- Acting for C4X Discovery Limited on its licence and collaboration agreement with Indivior PLC for its lead Orexin agonist compound.
- Acting for Abzena on the sale of the company to a fund managed by Welsh, Carson, Anderson & Stowe.
- Acting for NodThera on the discovery and development of next generation NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation, on a Series A financing round for a total of £28m.
Powell Gilbert LLP is well known for its outstanding IP offering, especially patents, where it has been involved in many headline and highly complex cases, many of which have reached the Supreme Court. Dr Penny Gilbert is the well-known team head and 'shrewd tactician' Tim Powell is a seasoned IP litigator combined with broad advisory and regulatory experience. The team handles multi-jurisdictional litigation, advice on SPCs, licensing and collaborations. With strong scientific backgrounds, Tim Whitfield, Dr Bethan Hopewell and 'brilliantly clever' associate Joel Coles are recommended.
‘They are a joy to work with, intensely intelligent and hard working. They are at the top table now for pharma patent cases – a force to be reckoned with.’
‘Tim Powell is a shrewd tactician. He is calm and authoritative. He has my full trust, and I can’t give much higher praise than that.’
‘Bethan Hopewell is an excellent addition to the PG partnership. She gets it – the balance required to execute on a complex strategy.’
‘Joel Coles is a rising star. Brilliantly clever and dogged in a fight.‘
- Represented Actavis, a leading manufacturer of generic pharmaceuticals, in its long-running battle with Warner-Lambert concerning the blockbuster drug pregabalin (marketed by Warner-Lambert as Lyrica).
- Successfully represented Biogen in proceedings before the UK High Court against AbbVie relating to biosimilars of AbbVie’s blockbuster drug Humira™ (adalimumab), currently the biggest selling prescription drug worldwide. The court granted the first ‘Arrow’ declaration and established the availability of such protection in circumstances where a patentee has multiple pending patent applications.
- Acting for Edwards Lifesciences in patent litigation – leading the UK case in the international patent battle over implantable heart valve repair devices.
- Defending Kymab, a UK biotech company spun out of the Sanger Centre in Cambridge, in a patent infringement action brought by Regeneron (a US biotechnology company and currently one of the largest worldwide). The case is listed to be heard by the Supreme Court in 2020. The team was also successful in the Court of Appeal agreeng that Kymab should be allowed to continue a number of clinically important collaborations, including its ongoing work with the Bill and Melinda Gates Foundation.
Clyde & Co LLP offers the full range of practice areas to its life sciences clients; in addition to corporate/commercial, product liability, IP and regulatory, it also provides public procurement, employment, property and tax teams. Ralph Cox has extensive experience in patent litigation and freedom to operate and acts for biotech and mid-sized and generic pharma companies. Corporate partner Simon Gamblin assists clients such as university spin-outs on complex licensing and commercialisation agreements including disputes arising from collaboration or licensing agreements. Claire Petts specialises in the areas of drug trials, product liability and claims/clinical negligence.
Ralph Cox; Simon Gamblin
Other key lawyers:
CNA Hardy/ITH PharmaLtd
The Doctors Laboratory Ltd/TDL Genetics Ltd
Oxford Biodynamics Plc
- Defending ITH Pharma in the product-liability claims brought against it alleging contamination of the baby food it manufactures.
- Defending GlaxoSmithKline in a product-liability claim arising from historic exposure to Myodil (a viscousiodine-containing oil injected by lumbar puncture for screening for pathology of the spinal cord).
- Advising Oxford Biodynamics Plc on an investment and cooperation agreement and drafting the documentation.
- Advising Oxsybio on a fundraising and drafting and negotiating the necessary documentation for this £10m deal.
- Defended TDL Genetics Ltd and The Doctors Laboratory in a series of patent infringement actions and appeals which included revocation and counterclaims involving patents relating to pre-natal testing for Down’s syndrome.
Cooley (UK) LLP offers a range of specialisms to its life sciences clients, in particular on transactional and IP matters. The highly experienced John Wilkinson assists clients in these areas and on regulatory and competition matters. Other core team members include Nicola Maguire, who advises on the IP aspects of transactions and Stephen Rosen.
DAC Beachcroft LLP has a well-established track record in dealing with significant pharmaceutical and medical product liability cases in the pharmaceutical and healthcare sectors. It excels in dealing with litigation and the regulatory issues connected with medical devices, clinical trials and consumer healthcare goods and pharmaceuticals. It frequently acts in connection with insurance claims and also handles related IP and commercial work. It has also formed a specialist MedTec offering. Alison Mcadams and Simon Pearl head the practice and Andrew Allan-Jones and Hamza Drabu are key advisors, the latter focuses on clinical research agreements and other commercial agreements.
Alison McAdams; Simon Pearl
‘They have excellent and wide knowledge of the sector – extensive medical device expertise. Olya Melnitchouk is a rising star and Simon Pearl and Alison McAdams are already top advisers.’
Novartis, Alcon and Sandoz N
BMI Healthcare N
NHS Resolution and NHS Blood and Transplant Service
Insurer clients specialising in insureds in the life sciences sector
including HDI, Newline, Zurich, Allianz, QBE, Catlin and CNA
- Represented BMI Healthcare Group/Spire Healthcare Group on metal-on-metal hip replacement litigation which involved over 500 claimants alleging that the early failure of replacement hip products has resulted in pain and muscle damage.
- Advised Novartis; Alcon, its eye care subsidiary and Sandoz, its generics subsidiary regarding claims, regulatory advice on medicines and devices and on clinical trial matters.
- Advised HDI on on a range of claims involving medicines and devices and also advised on regulatory matters, particularly regarding clinical trials.
- Assisted Optegra UK Limited regarding the recall of intraocular lens and subsequent claims and regulatory issues.
- Acting for NHS England in the Lyrica patent litigation between Warner-Lambert, Actavis and Mylan. The case involves a complete new look at second medical use patent claims and the role of doctors, pharmacists and NHS England in the prescription and dispensing of pharmaceuticals. We created a new type of court order extending Norwich Pharmacal principles which led to NHS England issuing prescribing guidelines to every CCG and pharmacy in England.
Fieldfisher is home to an impressive range of expertise in the IP litigation and transactional fields together with regulatory regimes, competition, data privacy and related tax law. Team head Nicole Jadeja has expertise in commercial and regulatory matters together with a focus on IP and has represented clients in UK and ECJ courts as well as the EPO. Nicola Bex has considerable expertise in the medical device field in addition to drafting supply and licensing agreements, including those relating to clinical trials. Beatriz San Martin specialises in IP disputes in the sector and Sarah Ellson spearheads the regulatory team and advises on biosciences regulations. Former co-head of the team Alison Dennis is joining Taylor Wessing LLP in early 2020.
Align Technology Inc
Roche Products Ltd (pharmaceuticals) and Roche Diagnostics Limited (medical devices)
Genomics England Limited
Stifel Nicolaus Europe (formerly Oriel Securities)
- Acted for Roche Products in the judicial review of the NHS provision of its product bevacizumab (Avastin), the cancer drug. The Claimants were Bayer and Novartis and Roche was an interested party.
- Continuing to act for the Human Fertilisation and Embryology Authority on a long-running judicial review dispute with the Assisted Reproduction and Gynaecology Centre in relation to the decision to change the information and statistical data about licensed clinics which HFEA publishes on its website in the discharge of its duties, under section 8 of the Human Fertilisation and Embryology Act 1990.
- Advised Tristel plc, an AIM-listed life sciences company on its purchase of the Belgium-headquartered distribution business, Ecomed Group.
- Acting for Sandoz, the generics arm of Novartis, in a dispute concerning the interpretation of the Supplementary Protection Certificate Regulation. Sandoz is seeking revocation of GD Searle’s SPC for darunavir, an antiretroviral used for the treatment of HIV on the basis that the SPC is invalid. The matter was appealed and a number of questions were referred to the European Court.
- Acting for medical device company Align Technology on a range of matters, including drafting international agreements, technology licensing and advising on compliance, regulatory, tax and competition law in addition to IP disputes.
Goodwin has a track record acting for life sciences companies and investors on corporate transactions such as M&A and IPOs as well as securities offerings and venture capital financings. It is especially expert in advising on early stage financings. Graham Defries, Andrew Harrow and Sophie McGrath are key advisors in these areas. The team has been greatly boosted with the hire of Malcolm Bates, David Mardle, Tim Worden and Adrian Rainey who joined in mid 2019 from Taylor Wessing LLP and bring a wealth of life sciences-focused corporate, commercial transactional and regulatory expertise.
Other key lawyers:
Advance Medical Solutions Group Plc
AM-Pharma Holding BV
Staten Biotechnology BV
- Advised Staten Biotechnology on its strategic collaboration with Novo Nordisk A/S to develop novel therapeutics for the treatment of triglyceride dyslipidaemia.
- Advised Gadeta BV on its strategic collaboration with Kite, a Gilead company, to develop novel gamma delta T cell receptors therapies in various cancers.
- Advised Orchard Therapeutics on its $225m IPO of American Depositary Shares. JP Morgan, Goldman Sachs and Cowen served as the joint bookrunners on the deal. The proceeds will be put towards getting its three lead assets through regulatory filings for three gene therapies in the US and Europe.
- Acted for Novartis BioVentures and Versant Venture Capital VI, L.P. as lead investors in the £29m oversubscribed Series B equity funding round of Enterprise Therapeutics Limited.
- Acted for F-Prime Capital and Eight Roads Ventures in an investment into Owkin Inc, a US corporation with a French operating subsidiary working on an artificial intelligence software product to improve the accuracy of medical diagnoses.
Kirkland & Ellis International LLP has entered the rankings as a result of 'stand-out achiever' Nicola Dagg and her team joining forces with the firm. The team includes Daniel Lim, who is highlighted for his 'excellent understanding of biotech and regulations', and litigator Katie Coltart, who has a background in biochemistry. With a 'keen intellect and considerable knowledge' Senior associate Jin Ooi and Steven Baldwin are also core members of a team that has an established success rate in high-stakes patent litigation in the pharma and biosciences sectors. This is combined with the firm's financing and commercial capabilities.
‘Known for the highest-quality work to achieve the best results. Top of their game and must be on everyone’s list to consider using when a big matter needs an IP litigator.’
‘They demonstrate a clear ability to excel in high-pressure situations.’
‘Nicola Dagg is a stand-out achiever in the field. She leaves no stone unturned and is hugely in demand.’
‘The stand out individuals are Nicola Dagg, Jin Ooi and Katie Coltart. Nicola drives the technically strong and client-focused approach.’
‘Jin Ooi is an associate to watch out for. He has a keen attention to detail and will rapidly deploy his considerable knowledge of the facts and related case law to examine the situation at hand. He has a natural curiosity and strong intellect which lends well to valuable insights and contributions. He is also calm and meticulously organised which ensures the smooth and quick development of a case, no matter how many moving and complex parts there are.’
‘Daniel Lim has an excellent knowledge and understanding of biotech, as well as impressive knowledge of regulatory law.‘
- Acting for Regeneron Pharmaceuticals Inc in patent litigation against Kymab Ltd relating to Regeneron’s proprietary transgenic mouse platform for therapeutic antibody development, VelocImmune®. The matter has been listed for a Supreme Court hearing.
- Acted for Pfizer in respect of infringement and validity proceedings in relation to LYRICA® (pregabalin), Pfizer’s blockbuster pain medicine which accounted for some billions of dollars in revenue. This complex case went to the Supreme Court and the team also assisted in the co-ordination of parallel litigation in a number of other jurisdictions.
- Acting for Novartis (Afinitor) in protecting everolimus (sold as AFINITOR®, VOTUBIA® and CERTICAN®) in the UK, Europe and elsewhere. Conducted UK litigation, advising on patent strategies and secured an interim injunction to prevent the sale of generic everolimus.
- Acted for the consortium consisting of EQT and Luxinva (a wholly owned subsidiary of the Abu Dhabi Investment Authority) on the CHF 10.2bn exclusive negotiations for the EQT-led consortium to acquire Nestlé Skin Health. This included conducting the EU regulatory and IP due diligence for the deal.
- The team is acting for a global pharma client in respect of a large-scale merger. The team is handling the EU clearance and supervising clearances elsewhere.
Linklaters LLP's healthcare practice is led by TMT/IP partner Marly Didizian and corporate partner Aisling Zarraga. It offers a full service to its clients from corporate/M&A, commercial and funding to technology and IP in combination with a global network. It also handles investigations and data-protection issues in the pharmaceutical industry. Working with US and European colleagues, Yohan Liyanage focuses on IP and is handling a number of patent disputes. Georgina Kon assists clients from a technology perspective, including with data-protection issues.
Marly Didizian; Aisling Zarraga
- Continues to act for the Sanofi group and Regeneron Pharmaceuticals Inc. as co-defendants in a complex, high-value UK patent litigation action brought by Amgen. The dispute relates to a revolutionary new class of medical treatments that lower the level of cholesterol in the body.
- Acting for Shire Pharmaceuticals in a complex UK patent litigation action brought by CSL Behring. The dispute relates to the treatment of a rare, life-threatening blood disorder known as hereditary angioedema.
- Acted as lead transaction counsel on Takeda Pharmaceutical Company’s $62bn takeover offer for the innovative pharmaceutical company Shire plc.
- Advising US-based Merck & Co in defending a long-running, high-profile trade mark infringement and breach of contract dispute against German-based Merck KGaA regarding use of the ‘MERCK’ name (the parties were originally part of the same company but are now separate).
Morgan, Lewis & Bockius UK LLP offers global expertise to life sciences clients, including in the biotech arena, especially on transactions, fund raisings and regulatory regimes. It can also bring in extensive competition/anti-trust expertise (Frances Murphy) while Timothy Corbet specialises in advising early stage biotechnology companies on capital raisings, listings and commercial matters. Thomas Cartwright assists on a range of corporate matters and 'trusted and extremely knowledgeable' consultant Paul Ranson enhances the team with his wealth of regulatory and commercial know-how relating to the life sciences sector.
Thomas Cartwright; Timothy Corbett
‘A trusted, credible team with great wealth of knowledge and experience. The work is always well communicated and delivered in a timely manner. Paul Ranson is a trusted, experienced and extremely knowledgeable partner. His work ethic, engagement and commitment in delivering agreed work are exceptional.’
Replimune Group Inc
Perrigo Company plc
Astellas Pharma Inc
SK Capital Partners
Shire Pharma (now Takeda)
Advanz Pharma (formerly Concordia)
- The team worked with uniQure NV, a Nasdaq-listed Dutch biotech company, in its registered $147m follow-on public offering of ordinary shares, which include the full exercise of the underwriter’s option to purchase additional shares.
- Advised biotechnology company Replimune Group Inc in connection with its initial public offering of common stock and listing on the Nasdaq Global Select Market.
- Handled all antitrust aspects for Alphabet/Google and Google’s sister subsidiary, Verily, in its proposed joint venture with ResMed, including approval from the European Commission after several months of scrutiny.
- Advise AstraZeneca on a range of complex competition issues, including new and novel means of supplying and pricing medicines for use in hospitals and in GP surgeries and for dispensing by pharmacies, all following the restructuring of the NHS’s buying practices by the government and following the establishment of Monitor, the new regulatory authority.
- Advising Bristol Myers Squibb in relation to a global policy review and implementation exercise.
The practice at Norton Rose Fulbright includes Ian Giles, who handles anti-trust/competition matters for life sciences clients, and Milana Chamberlain, a corporate finance lawyer who brings 'huge knowledge and passion' to her specialism in business ethics and anti-corruption. She advises clients on areas such as the UK Modern Slavery Act and human rights in supply chains. The team's varied skills assist clients ranging from big pharma to biotech startups.
‘Norton Rose Fulbright have a strong life science team with a good blend of functional expertise and they are all nice people to deal with – lawyers with a human touch.’
‘Milana Chamberlin has provided excellent advice and guidance with huge knowledge and passion for her subject.’
Malin Corporation Plc
Oxford Nanopore Technologies
- Representing Oxford Nanopore Technologie in patent litigation brought against it by Pacific Biosciences of California. The client developed hugely disruptive technology in the DNA sequencing market, such that established player Pacific Biosciences (PB) is bringing various claims of patent infringement in the UK and the US.
- Advising a healthcare client on an ongoing investigation by the Competition and Markets Authority into alleged excessive pricing contrary to the Chapter II prohibition.
- Advised a global client on copyright registration and brand protection in China.
- Advising a global client on the drafting of its distribution agreements with suppliers across the EU.
RPC's 'razor sharp and thoughtful' team is headed by Dorothy Flower who specialises in product liability defence cases relating to medical devices and pharmaceutical products. She acts for a range of manufacturers and suppliers, often on the instructions of insurers, and also handles claims arising from clinical trials. The team is entrusted with some high-profile work including actions relating to breast implants and 'metal hips on metal' disputes; Peter Rudd-Clarke specialises in cases involving orthopaedic implant litigation. Rowan Brown is also experienced in these areas and Genevieve Isherwood assists on medical malpractice and product liability claims.
Other key lawyers:
‘The team demonstrates great understanding of our needs and a commitment to getting it right for us. It feels like more than just doing their jobs. They think strategically, give us alternative viewpoints, and have incredible attention to detail. I think of these individuals as colleagues.’
‘Dorothy Flower is just brilliant, always there for us, and we have really enjoyed working with Genevieve Isherwood on recent issues – to the point where I will be sad when our current case is concluded!‘
‘These lawyers are razor sharp yet compassionate, thoughtful, and committed to getting the best outcome for us.’
Make Yourself Amazing
Royal Hospital for Neuro-Disability
NQBE European Operations
British Pregnancy Advisory Service
Merete Medical GmbH
- Represented Corin in the ‘metal-on-metal’ group litigation involving some 157 claims.
- Representing the British Pregnancy Advisory Service in an application for judicial review over abortion legislation.
- Assisting BioPoly, a US-based orthopaedic medical device manufacturer. Current work relates to a post-market registry study in the UK for a new type of knee prosthesis product. Also provided regulatory and IP advice and assistance with the contractual agreements for the study.
- Acted for Merck Sharp & Dohme Limited and its insurers Chubb with regard to a clinical trial brought by a trial subject who alleged complex, adverse consequences of participation.
- Representing Bard Pharmaceuticals Limited in the defence of a claim being made against it for an alleged, accidental, opioid overdose.
Slaughter and May's client list ranges from some of the largest international life sciences companies through to start-ups, universities and research institutions, as well as investors, and it counts GlaxoSmithKline as a key client. It provides multi-jurisdictional cover and is especially adept in the realms of corporate/M&A and finance deals where it provides a 'flawless' service. David Johnson spearheads corporate and commercial transactions together with Simon Nicholls. Susie Middlemiss takes on contentious and non-contentious IP matters.
David Johnson; David Johnson
Other key lawyers:
‘The team communicates very well internally so that there is never a lack of knowledge in case somebody else has to cover. The service is therefore flawless and consistent.‘
Thermo Fisher Scientific
- Advising GlaxoSmithKline plc on its agreement with Pfizer Inc. to combine their consumer health businesses into a new joint venture with combined sales of approximately £9.8bn. GSK will have a majority controlling interest of 68% and Pfizer will have an equity interest of 32% in the joint venture.
- Advised Shire plc on the takeover offer by Takeda Pharmaceutical Company Limited for the entire issued, and to be issued, ordinary share capital of Shire.
- Advised GlaxoSmithKline plc on its acquisition of Novartis AG’s 36.5% stake in their Consumer Healthcare Joint Venture for a cash consideration of $13bn.
- Advised Amyris Inc on its collaboration arrangements with a subsidiary of Yifan Pharmaceutical.
- Advising Thermo Fisher Scientific on its proposed acquisition of the electron microscope peripherals business of Roper Technologies Inc (the Gatan business). In addition to advising on the UK filing, it is coordinating with local counsel with respect to filings in the US and Austria, a matter valued at c.$925m.
Stephenson Harwood serves a range of pharma, biotech and healthcare clients, including startups, with a comprehensive range of expertise. This includes corporate and commercial; Andrew Edge has advised a number of major players in the sector on mergers, acquisitions and IPOs and Anthony Clare also advises on commercial and funding mandates. Alexandra Pygall 'provides the highest quality advice' to her clients on all aspects of IP commercialisation including licensing and collaboration deals and routinely assists on the IP aspects of M&A. 'Excellent advisor' Rob Jacob also specialises in all aspects of IP advisory and contentious cases.
Andrew Edge; Alexandra Pygall
Other key lawyers:
Anthony Clare; Rob Jacob
‘High-quality advice, personable solicitors, great individual care and attention. A team who genuinely care and want to make a different to their clients whether to win, negotiate or settle.‘
‘Alexandra Pygall has an excellent technical background and provides the highest-quality advice.’
Shield Therapeutics Plc
Cell Medica Ltd
- Advised Shield Therapeutics in relation to the exclusive out-licensing arrangement negotiated with Norgine BV for the right to commercialise Feraccru (a treatment for iron deficiency) in Europe, Australia and New Zealand.
- Advised Piramal Enterprises Limited on the sale of Piramal Imaging SA to UK-based medical imaging services provider Alliance Medical Group, part of the Life Healthcare Group.
- Advises Astellas Pharma Europe Limited on a wide range of commercial contracts including service agreements and distribution agreements across multiple jurisdictions, in relation to Astellas’ marketed products, and logistics services agreements for delivery of products to pharmacies. Also advises on master agreements for the provision of marketing and regulatory affairs services and data protection.
- Advising GlaxoSmithKline Plc on multi-jurisdictional trade mark, copyright, comparative advertising and unfair competition claims brought by GSK in relation to various duplications of the shape of an inhaler designed, manufactured and licensed by Celon Pharma SA, a Polish pharmaceutical company. .
- Advised AIM-listed life sciences company TyraTech in relation to the UK aspects of the merger with American Vanguard Corporation and the cancellation of admission of TyraTech’s common stock to trading on AIM.
Taylor Wessing LLP's life sciences team includes Nigel Stoate, who heads up the patents practice and specialises in contentious work in a variety of industries in addition to life sciences. Simon Cohen also handles patent litigation together with pharma regulatory work and James Marshall is a patent litigator with a focus on the pharmaceuticals and telecommunications sectors. The firm can offer its life sciences clients an impressive range of expertise in areas including competition and capital markets. Malcolm Bates, David Mardle, Tim Worden and David Rainey have left the practice to join Goodwin. Alison Dennis has joined the team from Fieldfisher.
Well known for its outstanding patent protection and enforcement capabilities, Carpmaels & Ransford LLP acts for an impressive range of big pharma and biotech clients. It also helps smaller and startup clients, many of which are involved in cutting-edge science, to grow. In addition to providing end-to-end patent abilities, it assists clients with areas such as licensing and collaborations. Specialist partners spearhead this work - David Wilson, Hugh Goodfellow, Mark Chapman and James Warner - backed up by skilled teams. Patent litigator Simon Llewellyn has joined the team from Bird & Bird LLP.
David Wilson; Hugh Goodfellow; Mark Chapman; James Warner
Other key lawyers:
Abraxis Bioscience (Owned by the Celgene biotechnology group)
Foundation Hubrecht Organoid Technology
Janssen Biotech, Inc. (a Johnson & Johnson company)
Johnson and Johnson
Pacific Biosciences, Inc.
Stanford University / Forty Seven, Inc.
4D Pharma PLC
- Acted for Abraxis BioScience LLC (owned by the Celgene biotechnology group) on a referral to the European Court of Justice regarding the law relating to SPCs. Abraxis’s SPC application was based on the ABRAXANE® authorisation and a related patent.
- Acted for Novartis regarding a patent relating to its blockbuster medicine Exforge for the treatment of hypertension. Successfully defended the patent before the EPO against eight opponents and also provided extensive support in national litigation in numerous countries.
- Represented Pacific Biosciences, a California-based company specialising in real time DNA sequencing in two High Court patent infringement and revocation proceedings between PacBio and Oxford Nanopore Technologies, a UK-based company specialising in nanopore sequencing methods.
- Acted for Foundation Hubrecht Organoid Technology on worldwide patent and know-how licence agreement between Hubrecht Organoid Technology and JSR Corporation, the parent company of Crown Bioscience.
- Acted for Janssen Biotech (a Johnson & Johnson company) in a patent revocation action relating to a patent for the treatment of psoriasis which was commenced by Lilly.
Dechert LLP is well regarded for its transactional and finance work in the life sciences sectors. It advises on acquisitions, sales, IPOs as well as commercial work such as licensing and collaborations. Corporate partner, Douglas Getter is team head and the 'brilliant and incisive' Robert Darwin handles corporate and private equity matters for clients in the life sciences sector - he joined the team from Hogan Lovells International LLP in late 2018. US qualified Patrick Lyons is a capital markets lawyer with a strong focus on the life sciences sector.
Douglas Getter; Robert Darwin; Patrick Lyon
‘They are very service minded, accessible, with deep industry knowledge.’
‘They are a great support to their clients. Fantastic service attitude, engagement and industry knowledge. They are also fun to work with.‘
‘Robert Darwin is very well connected for a partner his age. Highly engaged, and outstanding technical skills.’
‘Robert Darwin is an up-and-coming corporate/PE professional, with astonishing experience and industry knowledge. He is a very adept negotiator who knows when to be tough and when to be pragmatic.’
Judges Scientific plc
- Advising new client Merck KGaA on its its strategic immuno-oncology collaboration with F-star, a clinical-stage biopharmaceutical company, including in relation to an acquisition option valued at up to $1bn.
- Advised MedinCell on its IPO on the regulated market of Euronext. MedinCell is a technology-based pharmaceutical company and the deal is valued at €35m.
- Advising a new life sciences research company on the strategic options relating to the potential sale of the company.
- Advising a new R&D client in connection with a clinical trial agreement and a capital raising.
Latham & Watkins serves life sciences companies ranging from big pharma to small bio-techs and also counts funds investing in the sector among its clients. It also offers the advantage of a global network. It is largely focused on transactional work and corporate partner Robbie McLaren handles areas such as cross-border acquisitions, and capital raisings. Fellow co-head Gail E Crawford handles cases on the tech side and includes all aspects of data privacy as a specialism. Edward Barnett deals with M&A transactions, commercial and governance matters and includes GlaxoSmithKline as a client. Frances Stocks Allen and Emily Cridland are noted associates in the team.
Gail Crawford; Robbie McLaren
‘There is a uniformity in quality of service regardless of which lawyer is assigned to the task. They have a breadth of expertise across geographies and specific areas of M&A law.’
‘Edward Barnett makes himself available to provide the strong voice of authority during crucial periods of the negotiation.’
‘Frances Stocks Allen and Emily Cridland are both relatively young but come across as very seasoned in front of counterparties. Very responsive, hardworking, and just all-round pleasant people to work with.’
- Representation of JP Morgan as financial advisor and lead financial arranger to Takeda Pharmaceuticals in connection with the acquisition by Takeda Pharmaceutical Company of Shire, the Ireland-based biopharmaceutical company.
- Representation of GHX Europe GmbH, a subsidiary of Global Healthcare Exchange, in connection with its acquisition of the core business of Medical Columbus, a Germany-based developer of healthcare procurement software.
- Representation of Theramex, a global specialty pharmaceutical company dedicated to women’s healthcare, in connection with the acquisition of the international women’s healthcare assets of Teva Pharmaceutical Industries Ltd. A deal valued at $703m.
- Advising Siemens AG on the IPO of its Healthineers unit on the Regulated Market (Prime Standard) of the Frankfurt Stock Exchange, a matter valued at €4.2bn.
- Advised MeiraGTx Holdings plc, the holding company for a clinical stage gene therapy company, in connection with its IPO on the NASDAQ.
James Fry heads the Mills & Reeve LLP multi-practice life sciences offering which is valued for its 'in-depth biotech sector knowledge'. Fry brings wide experience of transaction in the technology/digital health and IP fields including research collaborations and clinical trial agreements. Mark Pearce handles contentious and non-contentious IP matters and the team also provides expertise in areas including employment (Melanie James) and corporate finance (Zickie Lim). Other IP experts in the team include Alasdair Poore.
‘Mills & Reeve have a strong focus on the biotech sector and are also well placed to meet the needs of small- and medium-sized companies, who typically have small- and medium-sized legal budgets. They also provide a high level of partner contact time. These attributes differentiate them from their peers.’
‘They have very good engagement with the biotech/pharma community, facilitating networking within the industry. All partners and associates we work with are briefed on precedents and ways the firm has in the past preferred to handle matters, whilst always mindful that current circumstances/business climate may warrant a different approach. Exceptional availability and responsiveness.’
‘I have valued the work that James Fry has done for us. He takes a practical/ commercial approach and I have been impressed with his ability to grasp some quite complicated aspects of our work.’
The Mishcon de Reya LLP team helps a broad range of life sciences clients on both contentious and non-contentious cases in the IP and regulatory spheres, in addition to areas including contractual and competition law disputes. It also has a noteworthy track record in obtaining search and seizure orders against counterfeiters in the pharmaceutical sector. Martyn Hann leads this work and David Rose has expertise in all areas of IP protection including data base rights. Managing associate Stefania Littleboy specialises in non-contentious matters including joint ventures, licensing and co-existence agreements.
Dr Reddy’s Laboratories (UK) Limited
Perrigo Group (including Rafton Laboratories, Elan Pharmaceuticals, Rosemont Pharmaceuticals and Omega Pharma)
OBG Pharmaceuticals (including Pharmaserve Northwest Limited)
Lupin Limited and Lupin (Europe) Limited
- Acted for the claimant, Lupin, in successful proceedings invalidating Gilead’s SPC relating to Gilead’s Truvada product.
- Representing Dr Reddy’s Laboratories in defending a claim for patent infringement brought by Warner-Lambert/Pfizer in relation to pregabalin and Dr Reddy’s counterclaim for revocation.
- Advised a leading pharmaceutical company on an extremely serious data theft issue.
- Acted for a number of companies with regard to the law and regulation relating to the cultivation of cannabis and the subsequent use of extracts for the use in healthcare products.
- Advising a number of global and UK life sciences companies on GDPR and data protection matters, including in respect of particularly in respect of clinical data sharing and clinical data automisation
Osborne Clarke LLP
Janita Good leads Osborne Clarke LLP's offering to its life sciences clients which is focused on transactional work, strategic investments, joint ventures and cross-border M&A deals. Recent work has included IPOs, business restructurings and debt and equity restructuring. Matthew Edwards joined the team in January 2019 and Mathew Oliver has joined from Bird & Bird LLP.
Sensyne Health plc
Takeda Pharmaceuticals Company
Grifols SA and Grifols UK Limited
Millennium Pharmaceuticals Inc
UniPhar Group plc
Green Biologics Limited
Stryker European Operations BV
Universal Health Services Inc
- Advised Sensyne Health plc in connection with its group reorganisation and successful £225m AIM market IPO, the first healthcare AI flotation.
- Advised Takeda on its $105m option to acquire Akaza Bioscience Limited; the transaction includes an initial equity investment and complex licence agreements.
- Advised Millennium Pharmaceuticals Inc on amendments of its $100m option to acquire GammaDeltaTherapeutics – the revised deal structure was proposed in 2018 to incentivise certain key employees.
- Advised Biotecnol on the sale of its immuno-oncology pipeline and respective technologies to Chiome Bioscience Inc.
- The team is the sole advisor to Grifols SA and Grifols UK Limited, the global healthcare company (bioscience, diagnostic and hospital).
The Squire Patton Boggs team, led by Andrew Wilkinson, handles commercial and regulatory work as core specialisms and is known for its advertising, promotional clearance and product labelling know-how. Consultant Adrian Spooner, who is also a qualified pharmacist, acts for life sciences clients in respect of regulatory, IP and commercial matters and Paul Jinks' expertise includes commercial work relating to R&D, supply arrangements and product recall cases.
Charlotte Tillett heads the Guildford-based Stevens & Bolton LLP team whose core work for life sciences clients encompasses IP, regulatory, commercial and competition matters. Tillett, who has a science background, leads on much of the IP commercialisation work including licensing, joint development agreements and IP restructuring. Michael Frisby handles the litigation, arbitration and ADR work and Beverley Flynn undertakes commercial work on an array of contracts as well as data protection issues. Gustaf Duhs has expertise in competition, EU Law and regulatory issues in the life sciences sector.
Institute of Cancer Research
Lambda Therapeutic Ltd
Accord Healthcare Limited
Chas A Blatchford & Sons Ltd
Sanofi Synthelabo Ltd
Scitech Engineering Ltd
Lonza Biologics Plc
Zeta Biopharma GmbH
Rayner Intraocular Lenses Limited
iCareHealth (UK) Ltd
- Advising SecurMed, the lead entity on the UK’s implementation of the Falsified Medicines Directive and associated Delegated Regulation.
- Advising Lonza Biologics plc in relation to its patent and know-how licensing which included the negotiation of in and out licences relating to gene expression technology patents.
- Continuing to advise The Institute of Cancer Research on two large, specialist R&D projects.
- Advised Royal Philips, a global leader in health technology, on its acquisition of the entire issued share capital of medical device specialist Remote Diagnostic Technologies Limited. This included advising on merger control risks and associated regulatory issues.
- Advising Chas A Blatchford & Sons ‘in the matter of Otto Bock HealthCare North America Inc Federal Trade Commission’ inquiry and case.